The grades of three Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. OncoGenex Pharmaceuticals is a biopharmaceutical company that develops and commercializes new cancer therapies that address treatment resistance in cancer patients. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, OGXI also gets A’s. For more information, get Portfolio Grader’s complete analysis of OGXI stock.

Maxygen (NASDAQ:MAXY) earns a B this week, jumping up from last week’s grade of C. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock has a trailing PE Ratio of 3.5. For more information, get Portfolio Grader’s complete analysis of MAXY stock.

Allos Therapeutics (NASDAQ:ALTH) is seeing ratings go up from a C last week to a B this week. Allos is a biopharmaceutical company focused on developing and commercializing small-molecule drugs that treat cancer. For more information, get Portfolio Grader’s complete analysis of ALTH stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.